Common use of Commercial Development Plan Clause in Contracts

Commercial Development Plan. The Licensee will develop, manufacture and market the immunotherapy product PANVAC® and other Vaccine candidates such as Brachyury containing vaccine for therapy of colorectal cancer. Steps followed by Licensee to develop and commercialize PANVAC and other Vaccine candidates such as Brachyury containing vaccine are summarized below: [***] APPENDIX F — EXAMPLE ROYALTY REPORT Required royalty report information includes: · XXX license reference number (L-XXX-200X/0) · Reporting period · Catalog number and units sold of each Licensed Product (domestic and foreign) · Gross Sales per catalog number per country · Total Gross Sales · Itemized deductions from Gross Sales · Total Net Sales · Earned Royalty Rate and associated calculations · Gross Earned Royalty · Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made · Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8 % Royalty Due 11,460 Less Creditable Payments 10,000 Net Royalty Due 1,460 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 APPENDIX G — ROYALTY PAYMENT OPTIONS The XXX License Number MUST appear on payments, reports and correspondence.

Commercial Development Plan. The Licensee will develop, manufacture and market the immunotherapy product PANVAC® and other Vaccine candidates such as Brachyury containing vaccine for therapy of colorectal cancerbreast, non-small cell lung and other cancers within the Licensed Field of Use. Steps followed by Licensee to develop and commercialize PANVAC and other Vaccine candidates such as Brachyury containing vaccine are summarized below: [***] APPENDIX F — F- EXAMPLE ROYALTY REPORT Required royalty report information includes: · XXX license reference number (L-XXX-200X/0) · Reporting period · Catalog number and units sold of each Licensed Product (domestic and foreign) · Gross Sales per catalog number per country · Total Gross Sales · Itemized deductions from Gross Sales · Total Net Sales · Earned Royalty Rate and associated calculations · Gross Earned Royalty · Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made · Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8 % Royalty Due 11,460 Less Creditable Payments 10,000 Net Royalty Due 1,460 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 APPENDIX G — ROYALTY PAYMENT OPTIONS The XXX License Number MUST appear on payments, reports and correspondence.